6108 — New Ray Medicine International Holding Income Statement
0.000.00%
Last trade - 00:00
- HK$60.19m
- -HK$43.48m
- HK$50.15m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 119 | 133 | 335 | 89.8 | 50.2 |
Cost of Revenue | |||||
Gross Profit | 14.9 | 10.9 | 28.5 | -34.8 | 11.3 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 163 | 177 | 335 | 165 | 68.4 |
Operating Profit | -44 | -43.4 | 0.215 | -75.5 | -18.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -43.8 | -69.9 | -3.61 | -80.3 | -22.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -44.1 | -69.7 | -2.82 | -77.9 | -22.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -44.1 | -69.7 | -2.82 | -77.9 | -22.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -44.1 | -69.7 | -2.82 | -77.9 | -22.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.018 | -0.025 | -0.001 | -0.047 | -0.012 |